INTRAVITREAL BEVACIZUMAB FOR TREATMENT OF PROLIFERATIVE AND NONPROLIFERATIVE TYPE 2 IDIOPATHIC MACULAR TELANGIECTASIA

Overview of attention for article published in Retina, October 2011

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (65th percentile)
Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

twitter: 1 X user

patent: 5 patents

Readers on

mendeley: 36 Mendeley

So far, Altmetric has seen 5 patents that reference this research output.

Use of encapsulated cell therapy for treatment of ophthalmic disorders

Grant US-12485087-B2

United States of America

02 Dec 2025

Use of encapsulated cell therapy for treatment of ophthalmic disorders

Grant US-12357566-B2

United States of America

15 Jul 2025

Use of encapsulated cell therapy for treatment of ophthalmic disorders

Grant US-11207266-B2

United States of America

28 Dec 2021

Use of encapsulated cell therapy for treatment of ophthalmic disorders

Grant US-10456356-B2

United States of America

29 Oct 2019

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 1 additional patents.